IPM Take
The sharp issue is not whether digital mental health tools can help. Some probably can. The problem is that health systems are being asked to adopt them while evidence on comparators, patient-relevant outcomes, quality of life, delivery costs, resource use and adverse events remains uneven. For IPM, this is where digital mental health moves from innovation promise into HTA reality: access should expand, but only with evidence rules strong enough to protect patients and public budgets.
Executive Summary
A 2026 JMIR Mental Health study reviewed NICE evaluations of digital mental health technologies. It included nine NICE evaluations covering anxiety, depression, psychosis, insomnia, ADHD and tic disorders, with 30 digital mental health technologies and 78 supporting studies. The authors found repeated evidence gaps around effectiveness compared with relevant comparators, outcome selection, health-related quality of life, cost of delivery, resource impact and adverse-event reporting.
Why it matters
- HTA bodies: Need evidence standards that can evaluate digital tools across effectiveness, safety, cost-effectiveness and real-world service impact.
- Payers: Should avoid treating digital tools as automatically cost-saving unless evidence shows how they affect resource use, delivery costs and outcomes.
- Clinicians / patients: Need confidence that recommended tools are safe, useful, monitored and appropriate for the condition and care pathway in which they are used.
Previously, digital mental health tools were often framed as a quick answer to service pressure: scalable, lower-barrier and easier to deploy than traditional care. That promise remains attractive, especially where mental health systems are overloaded.
What has changed is the level of evidence scrutiny. NICE has already evaluated digital technologies across common and neurodevelopmental mental health conditions, but the JMIR analysis shows that many evidence packages still leave important uncertainties. These include whether tools perform better than relevant comparators, whether studies measure outcomes that matter to patients and whether developers adequately report adverse events, cost and resource use.
The affected populations include people using digital support for anxiety, depression, psychosis, insomnia, ADHD and tic disorders. This is not one narrow eligibility group. It is a wider access question about which digital tools should enter routine care, under what evidence conditions and with what follow-up.
For IPM, the implementation message is direct: digital access is not automatically better access. If tools are adopted without robust evidence, monitoring and clear use criteria, weak evidence can become embedded into routine care. Digital mental health needs the same discipline expected from other personalised medicine tools: defined use, validated benefit, safety oversight and accountability.
